As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
14 Analysts have issued a Olema Pharmaceuticals Inc forecast:
14 Analysts have issued a Olema Pharmaceuticals Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -142 -142 |
30%
30%
|
EBIT (Operating Income) EBIT | -143 -143 |
30%
30%
|
Net Profit | -129 -129 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Sean Bohen |
Employees | 85 |
Founded | 2006 |
Website | olema.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.